00:00If you look at yesterday's news specifically, I think that's a step forward and it's progress and you've seen the markets see that as well because it's about constructive dialogue between the government and industry and make no mistake, the US is by far the biggest priority market for our industry because it's the best country in the world to discover and develop innovation so far, by the way, there are others that are coming up very fast.
00:29But it's also the best place for some people to be able to access that innovation early and if we want to lower the cost of healthcare, we have to continue to encourage innovation but at a cost that is sustainable for payers, affordable for patients when they're paying to a certain degree out of pocket but also sustainable for us because we have to cover the cost of failure in a pipeline because most things don't work.
00:58Absolutely, GSK is engaging constructively and the state visit just, I can't remember if it was last week or two weeks ago, we were very present and I made the announcement that we were committed to invest $30 billion over the next five years in R&D and advanced manufacturing.
01:20And, you know, we're very confident and committed in betting big on the US and that includes having these kind of constructive dialogues around pricing and access.
Be the first to comment